Zhou Zhen, Chowdhury Enayet K, Breslin Monique, Curtis Andrea J, Reid Christopher M, Nelson Mark
Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool street, Hobart TAS 7000, Australia.
School of Population Health, Curtin University, Perth, Australia.
Heart Lung. 2022 Jan-Feb;51:40-45. doi: 10.1016/j.hrtlng.2021.09.005. Epub 2021 Oct 29.
Antihypertensives and lipid-lowering therapy (LLT) are often used concurrently.
To determine whether there was a difference in clinical outcomes when older patients with LLT were prescribed angiotensin-converting-enzyme-inhibitors (ACE-Is) compared with diuretics.
This analysis included 648 LLT older users free of cardiovascular disease (CVD) from a trial comparing ACE-I versus diuretic-based therapy. Comparisons were made between LLT+ACE-I (n = 335) and LLT+diuretic groups (n = 313) using multivariable Cox proportional-hazard models. Primary endpoints were all-cause and CVD mortality (in-trial [4.1-year]+post-trial [6.9-year]) and secondary endpoints (in-trial) were the composite of all-cause mortality and first CVD events and its components, CVD mortality and incident diabetes.
There were no significant differences between the two groups for the primary endpoints over the in-trial plus post-trial follow-up, nor was there a difference for any secondary outcomes over the in-trial follow-up.
The LLT+ACE-I and LLT+diuretic combinations showed similar effects in CVD-free older individuals. Randomised trials are needed to provide conclusive evidence.
抗高血压药与降脂治疗(LLT)常联合使用。
确定在接受LLT的老年患者中,与使用利尿剂相比,使用血管紧张素转换酶抑制剂(ACE-Is)时临床结局是否存在差异。
本分析纳入了一项比较基于ACE-I与基于利尿剂治疗的试验中648名无心血管疾病(CVD)的LLT老年使用者。使用多变量Cox比例风险模型对LLT+ACE-I组(n = 335)和LLT+利尿剂组(n = 313)进行比较。主要终点为全因死亡率和CVD死亡率(试验期[4.1年]+试验后期[6.9年]),次要终点(试验期内)为全因死亡率与首次CVD事件的复合终点及其组成部分,即CVD死亡率和新发糖尿病。
在试验期加试验后期随访期间,两组主要终点无显著差异,在试验期随访期间任何次要结局也无差异。
LLT+ACE-I和LLT+利尿剂组合在无CVD的老年人中显示出相似的效果。需要进行随机试验以提供确凿证据。